Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | PDK1 | Q15118 | 14/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 14/20 | 0.56 |
| ▸ | PDK3 | Q15120 | 14/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 14/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.45 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.45 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.45 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568795 | 0.89 | ABCB11 (0.74) | ABCB11PDK1PDK2PDK3PDK4 | |
| SCHEMBL6568788 | 0.89 | ABCB11 (0.74) | ABCB11PDK1PDK2PDK3PDK4 | |
| SCHEMBL27553243 | 0.87 | PDK1 (0.53) | ABCB11PDK1PDK2PDK3PDK4 | |
| SCHEMBL6572441 | 0.87 | MAPT (0.63) | ABCB11PDK1PDK2PDK3PDK4 | |
| SCHEMBL6449596 | 0.87 | ABCB11 (0.59) | ABCB11PDK1PDK2PDK3PDK4 | |
| SCHEMBL6570069 | 0.85 | PDK1 (0.60) | ABCB11PDK1PDK2PDK3PDK4 | |
| SCHEMBL6345950 | 0.82 | PDK1 (0.49) | ABCB11PDK1PDK2PDK3PDK4 | |
| SCHEMBL5735090 | 0.82 | HTT (0.69) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL5737946 | 0.80 | PDK1 (0.66) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL6568169 | 0.79 | PDK1 (0.67) | ABCB11PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960688-B2 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2005-11-01 | — | — | US | disclosed |
| EP-1082110-B1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-03-24 | — | — | EP | disclosed |
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ZENECA LIMITED | 2004-01-15 | — | — | US | disclosed |
| US-6498275-B1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | PDHA1, PDK1, PDHB | ABCB11 325/4885PDK1 2/4885PDK2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.